Az asthma farmakogenomikája: Jelen és perspektíva

Translated title of the contribution: Pharmacogenomics of asthma: Present and perspective

C. Szalai, Gergely Tölgyesi, Adrienne Nagy, A. Falus

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One main area of pharmacogenomics is the discovery of new drugs and drug targets with molecular genetic or genomic methods; the other is the study of how genomic differences influence the variability in patients responses to drugs. In this review the authors summarise the most important results of this latter issue. Despite the availability of three major classes of therapeutic agents for asthma, it has been estimated that as many as half of asthmatic patients do not respond to treatment with β2-agonists, leukotriene modifiers or inhaled corticosteroids. Moreover, in some individuals asthma therapy has been associated with serious adverse drug reactions. An estimated 60 to 80% of variability in individual responses to therapy may have genetic bases. All of the currently available data on asthma pharmacogenomics originated from genetic variations in genes of the drug treatment target or target pathways. Results of genetic association studies that investigate responses to β2-agonist, leukotriene modifier and corticosteroid therapy will be summarised and recent findings in the literature highlighted. Although, at present pharmacogenomics can explain only a fraction of the adverse drug responses, hopefully these results mark the clinical use of genotyping at an individual level as adjunct to pharmacotherapy for asthma and many other diseases.

Original languageHungarian
Pages (from-to)159-169
Number of pages11
JournalOrvosi Hetilap
Volume147
Issue number4
Publication statusPublished - Jan 29 2006

Fingerprint

Pharmacogenetics
Asthma
Leukotrienes
Pharmaceutical Preparations
Adrenal Cortex Hormones
Therapeutics
Genetic Association Studies
Drug Discovery
Drug-Related Side Effects and Adverse Reactions
Molecular Biology
Drug Therapy
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az asthma farmakogenomikája : Jelen és perspektíva. / Szalai, C.; Tölgyesi, Gergely; Nagy, Adrienne; Falus, A.

In: Orvosi Hetilap, Vol. 147, No. 4, 29.01.2006, p. 159-169.

Research output: Contribution to journalArticle

Szalai, C, Tölgyesi, G, Nagy, A & Falus, A 2006, 'Az asthma farmakogenomikája: Jelen és perspektíva', Orvosi Hetilap, vol. 147, no. 4, pp. 159-169.
Szalai, C. ; Tölgyesi, Gergely ; Nagy, Adrienne ; Falus, A. / Az asthma farmakogenomikája : Jelen és perspektíva. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 4. pp. 159-169.
@article{210c59123872481f81942718e559ae33,
title = "Az asthma farmakogenomik{\'a}ja: Jelen {\'e}s perspekt{\'i}va",
abstract = "One main area of pharmacogenomics is the discovery of new drugs and drug targets with molecular genetic or genomic methods; the other is the study of how genomic differences influence the variability in patients responses to drugs. In this review the authors summarise the most important results of this latter issue. Despite the availability of three major classes of therapeutic agents for asthma, it has been estimated that as many as half of asthmatic patients do not respond to treatment with β2-agonists, leukotriene modifiers or inhaled corticosteroids. Moreover, in some individuals asthma therapy has been associated with serious adverse drug reactions. An estimated 60 to 80{\%} of variability in individual responses to therapy may have genetic bases. All of the currently available data on asthma pharmacogenomics originated from genetic variations in genes of the drug treatment target or target pathways. Results of genetic association studies that investigate responses to β2-agonist, leukotriene modifier and corticosteroid therapy will be summarised and recent findings in the literature highlighted. Although, at present pharmacogenomics can explain only a fraction of the adverse drug responses, hopefully these results mark the clinical use of genotyping at an individual level as adjunct to pharmacotherapy for asthma and many other diseases.",
keywords = "β-agonists, Corticosteroids, Genes, Genetic variations, Leukotriene modifiers, SNP",
author = "C. Szalai and Gergely T{\"o}lgyesi and Adrienne Nagy and A. Falus",
year = "2006",
month = "1",
day = "29",
language = "Hungarian",
volume = "147",
pages = "159--169",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Az asthma farmakogenomikája

T2 - Jelen és perspektíva

AU - Szalai, C.

AU - Tölgyesi, Gergely

AU - Nagy, Adrienne

AU - Falus, A.

PY - 2006/1/29

Y1 - 2006/1/29

N2 - One main area of pharmacogenomics is the discovery of new drugs and drug targets with molecular genetic or genomic methods; the other is the study of how genomic differences influence the variability in patients responses to drugs. In this review the authors summarise the most important results of this latter issue. Despite the availability of three major classes of therapeutic agents for asthma, it has been estimated that as many as half of asthmatic patients do not respond to treatment with β2-agonists, leukotriene modifiers or inhaled corticosteroids. Moreover, in some individuals asthma therapy has been associated with serious adverse drug reactions. An estimated 60 to 80% of variability in individual responses to therapy may have genetic bases. All of the currently available data on asthma pharmacogenomics originated from genetic variations in genes of the drug treatment target or target pathways. Results of genetic association studies that investigate responses to β2-agonist, leukotriene modifier and corticosteroid therapy will be summarised and recent findings in the literature highlighted. Although, at present pharmacogenomics can explain only a fraction of the adverse drug responses, hopefully these results mark the clinical use of genotyping at an individual level as adjunct to pharmacotherapy for asthma and many other diseases.

AB - One main area of pharmacogenomics is the discovery of new drugs and drug targets with molecular genetic or genomic methods; the other is the study of how genomic differences influence the variability in patients responses to drugs. In this review the authors summarise the most important results of this latter issue. Despite the availability of three major classes of therapeutic agents for asthma, it has been estimated that as many as half of asthmatic patients do not respond to treatment with β2-agonists, leukotriene modifiers or inhaled corticosteroids. Moreover, in some individuals asthma therapy has been associated with serious adverse drug reactions. An estimated 60 to 80% of variability in individual responses to therapy may have genetic bases. All of the currently available data on asthma pharmacogenomics originated from genetic variations in genes of the drug treatment target or target pathways. Results of genetic association studies that investigate responses to β2-agonist, leukotriene modifier and corticosteroid therapy will be summarised and recent findings in the literature highlighted. Although, at present pharmacogenomics can explain only a fraction of the adverse drug responses, hopefully these results mark the clinical use of genotyping at an individual level as adjunct to pharmacotherapy for asthma and many other diseases.

KW - β-agonists

KW - Corticosteroids

KW - Genes

KW - Genetic variations

KW - Leukotriene modifiers

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=33645642015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645642015&partnerID=8YFLogxK

M3 - Article

C2 - 16515024

AN - SCOPUS:33645642015

VL - 147

SP - 159

EP - 169

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 4

ER -